Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Abstract

The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

1 - 36 . (canceled) 
     
     
         37 . A pharmaceutical composition comprising at least one carbostyril derivative selected from the group consisting of DM-1458, DM-1454 and DCPP in combination with at least one serotonin reuptake inhibitor. 
     
     
         38 . The composition of  claim 37 , wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof. 
     
     
         39 . The composition of  claim 38 , wherein at least one serotonin reuptake inhibitor is citalopram. 
     
     
         40 . The composition of  claim 37 , further comprising at least one pharmaceutically acceptable carrier. 
     
     
         41 . A method of treating a subject afflicted with a mood disorder comprising:
 administering to the subject a pharmaceutical composition comprising at least one carbostyril derivative selected from the group consisting of DM-1458, DM-1454 and DCPP in combination with at least one serotonin reuptake inhibitor.   
     
     
         42 . The method according to  claim 41 , wherein the mood disorder is chosen from depression or major depressive disorder. 
     
     
         43 . The method according to  claim 41 , wherein the mood disorder is chosen from major depressive disorder, all mood disorders, schizoaffective disorder and dementia with depressive symptoms. 
     
     
         44 . A method of treating a subject afflicted with a mood disorder comprising:
 administering to the subject a pharmaceutical composition comprising at least one carbostyril derivative selected from the group consisting of DM-1458, DM-1454 and DCPP in combination with at least one serotonin reuptake inhibitor,   wherein the mood disorder is chosen from major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.